SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 /CenExel is pleased to announce its partnership with Metsera, Inc.

Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...

For older adults with type 2 diabetes, use of GLP-1 RAs is associated with a modestly lower risk for depression compared with DPP-4i use.

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

Biomea Fusion (BMEA) announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

Presentation to highlight new clinical data from COVALENT-111, including c-peptide dataREDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

GLP-1 Receptor Agonist Market. The global GLP-1 receptor agonist market is on the verge of unprecedented growth, fueled by ...